Company Overview
- Website
- cingulatetherapeutics.com
- Phone
- (913) 942-2300
- Employees
- 9
- Founded in
- 2012
- Industry
- Major Drugs
- SIC Code
-
2834 - Pharmaceutical Preparations
Financials & Stats
Revenue
$10B
Recent News & Media
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
- May 20, 2025
- biospace.com
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
- May 15, 2025
- biospace.com
Cingulate Inc Terminates Grant Agreement with Foundation
- May 13, 2025
- tipranks.com
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
- Apr 30, 2025
- biospace.com
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
- Mar 4, 2025
- biospace.com
Final Study Completed for Cingulate’s Lead Asset CTx-1301
- Jan 7, 2025
- biospace.com
Companies Similar to Cingulate Therapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to Cingulate Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 10M | 20 | Boston, MA | 2005 | |
| 10M | 3 | Richardson, TX | 2010 | |
| 10M | 460 | Miami, FL | 1998 | |
| 10M | 5 | Tampa, FL | 2008 | |
| 10M | 47 | Chandler, AZ |